Welcome to the Investor Relations section of the IXICO website

IXICO sells clinical data management and analysis products and services. Our technologies seek to improve diagnosis, assess progression and measure treatment outcomes of neuro-degenerative disorders including Huntington's disease, Multiple Sclerosis, Alzheimer's disease and other causes of dementia. We have commercial relationships with 9 out of the top 15 global pharmaceutical companies providing clinical trial services and are building on this core business as a digital healthcare technology provider for the diagnosis and management of dementia in clinical practice. Please see IXICO announces launch of dementia care digital platform with The NHSA Network for more details.

Our digital technologies are used in  

In October 2013, IXICO became a public company by listing on AIM via a reverse takeover of Phytopharm Plc which enabled IXICO to accelerate its investments in new product development.

We recognise the importance of providing clear and timely information to our existing and potential shareholders and hope that you will find our website interesting.

If you require further information please email us at

Note: IXICO is subject to the UK City Code on Takeover and Mergers; this site is provided for investors and is AIM Rule 26 compliant.

Share price and news information on this site is updated dynamically from external data feeds.